Higher mRNA expression of LPAR2 was associated with better OS in HNSC tumor stage 2–4 (stage 2, HR = 0.45 [0.2–0.99], P = 0.042; stage 3, HR = 0.35 [0.14–0.88], P = 0.019; stage 4, HR = 0.55 [0.38–0.79], P = 0.00094). This evidence concerns the gene LPAR2 and neoplasm.